At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 66 enrolled
Drug / intervention
AQ280 +1 moredrug
Likely dose
AQ280 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, and Food Effect Evaluation Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of AQ280 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating AQ280 and Placebo for Eosinophilic Esophagitis (EoE). Completed, enrolled 66 participants across 1 site.
Detailed Summary
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis (EoE)
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionJul 2023
TodayJul 2026
First PostedAug 3, 2022
Enrollment StartJul 20, 2022
Primary CompletionJul 10, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.9 years ago
Interventions
AQ280drug
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral
Placebodrug
Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral